Fortrea Holdings (FTRE) Aperçu de l'action
Fortrea Holdings Inc. est un organisme de recherche sous contrat qui fournit des solutions de développement de produits biopharmaceutiques et d'appareils médicaux à des clients pharmaceutiques, biotechnologiques et d'appareils médicaux dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
FTRE Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fortrea Holdings Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$13.22 |
| Plus haut sur 52 semaines | US$18.67 |
| Plus bas sur 52 semaines | US$3.97 |
| Bêta | 1.91 |
| Variation sur 1 mois | 34.90% |
| Variation sur 3 mois | 28.10% |
| Variation sur 1 an | 225.62% |
| Variation sur 3 ans | n/a |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -56.08% |
Nouvelles et mises à jour récentes
Recent updates
Mise à jour du récit • May 07
FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside
Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.
Mise à jour du récit • Apr 21
FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating
The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.Mise à jour du récit • Apr 07
FTRE: Margin Recovery Under New Leadership And Conservative 2026 Guidance May Drive Re Rating
Analysts nudged their price target for Fortrea slightly higher to $22.59 from $22.46, citing a mix of higher assumed profit margins, a lower future P/E multiple, and varied recent Street calls that balance upgraded ratings with trimmed targets in the $12 to $22 range. Analyst Commentary Recent Street research on Fortrea shows a wide range of opinions, but the most optimistic voices point to improving execution, clearer profit potential, and room for the shares to rerate as fundamentals stabilize.Mise à jour du récit • Mar 24
FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update The analyst price target for Fortrea has been revised lower from about $25 to roughly $22.46. This reflects analysts balancing recent price target cuts from several banks with more constructive views that cite improving execution, better fundamentals, and a clearer path to margin recovery under new leadership.
Mise à jour du récit • Mar 09
FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside
The analyst price target for Fortrea Holdings has shifted lower by about $2 to align with a refreshed fair value estimate of $14.44, as analysts factor in a higher discount rate, more cautious revenue growth assumptions, and only modestly revised margin and P/E inputs, despite recent rating upgrades and mixed target resets across the Street. Analyst Commentary Street research on Fortrea paints a mixed picture, with several firms turning more constructive on execution and earnings power, while others temper expectations for share price upside through lower targets.Mise à jour du récit • Feb 23
FTRE: Execution Improvements And Deleveraging Under New Leadership May Drive Re Rating
Narrative Update on Fortrea Holdings: Analyst Price Target Shift The updated analyst price target for Fortrea Holdings reflects a higher implied valuation in dollar terms. Analysts are citing improved execution under new leadership, a clearer path to margin recovery, and recent target increases from firms that now see better revenue trends, margin potential, and benefits from deleveraging.Article d’analyse • Feb 12
The Market Doesn't Like What It Sees From Fortrea Holdings Inc.'s (NASDAQ:FTRE) Revenues Yet As Shares Tumble 33%
Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have retraced a considerable 33% in the last month, reversing a fair...Mise à jour du récit • Feb 09
FTRE: Execution And Margin Recovery Under New Leadership Will Drive Future Upside
Narrative Update: Fortrea Holdings Our updated analyst price target for Fortrea moves higher by about $3, with analysts pointing to improving execution under new leadership, early commercial traction, a clearer path to margin recovery, and more supportive biopharma demand as key reasons for their revised expectations. Analyst Commentary Recent Street research on Fortrea reflects a more constructive tone, with several bullish analysts lifting price targets and upgrading ratings as they reassess the company’s execution, growth prospects, and margin potential.Mise à jour du récit • Jan 25
FTRE: Execution Gains And Biopharma Cycle Tailwinds May Drive Re Rating
Narrative Update on Fortrea Holdings Analysts have lifted their blended price expectations for Fortrea by several dollars, with new targets in the low to mid $20s and up to $25, citing improving execution under new leadership, a clearer path to margin recovery, and better perceived performance as the biopharma cycle picks up. This is broadly consistent with only modest tweaks to our discount rate, revenue growth, margin and future P/E assumptions and no change to our $25.00 fair value estimate.Mise à jour du récit • Jan 11
FTRE: New Leadership And Margin Recovery Path May Drive Re Rating
Analysts have raised their blended price target on Fortrea Holdings to about $25 from roughly $13, reflecting updated assumptions for stronger revenue growth, slightly improved profit margins, and a higher future P/E multiple, alongside recent upgrades and target increases from several firms. Analyst Commentary Bullish analysts are becoming more constructive on Fortrea Holdings, with a series of upgrades and price target increases that highlight improving company execution and a more supportive setup for profitability and valuation.Mise à jour du récit • Dec 27
FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks
Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.Mise à jour du récit • Dec 13
FTRE: Rapid Share Gains Will Face Test From Leadership Transition Execution
Analysts have raised their fair value estimate for Fortrea Holdings from $11.21 to $12.07 per share, citing a lower perceived discount rate, slightly stronger long term revenue growth assumptions, and improving demand signals reflected in multiple recent price target increases across the Street. Analyst Commentary Bullish analysts point to a constructive setup for Fortrea as recent price target increases cluster in a narrow range above the prior consensus, suggesting growing confidence that execution under new leadership can support a re-rating.Article d’analyse • Dec 07
Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have been powering on, with a gain of 27...Mise à jour du récit • Nov 29
FTRE: Rapid Share Price Increase Will Challenge Upside Amid Mixed Industry Trends
Analysts have raised their average price target for Fortrea Holdings. Recent targets have moved from approximately $7-11 previously to as high as $14, reflecting improving internal execution, stabilizing industry trends, and cautious optimism regarding future demand.Seeking Alpha • Nov 20
Fortrea Holdings: Showing Real Signs Of Life
Summary Fortrea Holdings has shown signs of recovery after severe operational and financial struggles, with shares rebounding from historic lows. The company reported improving sales momentum and a rising backlog, but EBITDA and margins remain under pressure, keeping leverage high. Management has implemented cost reductions, raised guidance, and enacted a shareholder rights plan, signaling renewed urgency and insider confidence. While the darkest scenarios seem less likely, conviction to buy remains low; continued monitoring is warranted as recovery progresses. Read the full article on Seeking AlphaMise à jour du récit • Nov 15
FTRE: Bookings Stability And Leadership Transition Will Shape Outlook Into 2026
Fortrea Holdings' analyst price target has increased significantly from $9.53 to $11.21, as analysts cite a more promising outlook supported by steady bookings, sector stabilization, and improving market demand. Analyst Commentary Recent analyst research highlights both positive developments and ongoing uncertainties for Fortrea Holdings.Mise à jour du récit • Nov 01
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
The analyst price target for Fortrea Holdings has been raised from $7 to a range between $9 and $10. Analysts cite stabilizing healthcare cost trends and improving contract research bookings as key factors for their more optimistic outlook.Mise à jour du récit • Oct 18
Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their price target for Fortrea Holdings from $8.30 to $9.44, citing sustained improvements in revenue growth, stabilizing cost trends, and recent industry signals that point to a bottoming in contract research organization demand. Analyst Commentary Recent analyst updates highlight a shifting outlook for Fortrea Holdings, with both optimistic and cautious perspectives emerging from the latest research notes.Mise à jour du récit • Oct 03
Global Demographic Trends Will Spur Clinical Advances
Analysts have raised their fair value estimate for Fortrea Holdings from $7.89 to $8.30 per share. They cite recent improvements in industry bookings and biotech funding, despite continued mixed demand signals.Mise à jour du récit • Sep 05
Global Demographic Trends Will Spur Clinical Advances
The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.Article d’analyse • Aug 14
Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?
NasdaqGS:FTRE 1 Year Share Price vs Fair Value Explore Fortrea Holdings's Fair Values from the Community and select...Mise à jour du récit • Aug 07
Global Demographic Trends Will Spur Clinical Advances
Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.Article d’analyse • Jun 21
Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching
Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...Nouveau récit • May 17
New Therapeutic Areas And AI Adoption Will Fuel Progress
Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.Article d’analyse • May 08
Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?
Key Insights Fortrea Holdings' estimated fair value is US$11.03 based on 2 Stage Free Cash Flow to Equity Fortrea...Article d’analyse • Apr 08
Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Mar 06
Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds
Summary FTRE's strong backlog of $7.7 billion provides revenue stability and planning advantages, despite short-term spin-off costs and missed earnings. The CRO market is projected to grow significantly, driven by increased outsourcing of complex late-stage trials, positioning FTRE for long-term growth. FTRE's global reach across 90 countries offers a competitive advantage in multi-region trials, enhancing patient enrollment and administrative efficiency. Post-spin-off, FTRE can focus on high-margin areas like oncology and decentralized trials, with expected margin improvements from reduced overhead costs. Read the full article on Seeking AlphaArticle d’analyse • Mar 04
Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet
To the annoyance of some shareholders, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares are down a considerable 38% in the...Article d’analyse • Dec 27
We Think Fortrea Holdings (NASDAQ:FTRE) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Dec 26
Fortrea: Turning Around As The Activists Move In
Summary Fortrea, a recent Labcorp spin-off, is poised for recovery with strong bookings, industry inflection, and activist interest, despite a 46% stock drop in 2024. CEO Thomas Pike's proven track record and the potential January Effect add to Fortrea's upside, targeting a $45 stock price within a year. The CRO industry's temporary downturn is reversing, with Fortrea's book-to-bill ratio improving to 1.23x, indicating strong future revenue growth. Fortrea's high leverage and ongoing spin-off expenses are concerns, but activist involvement and potential acquisition post-July 2025 offer additional upside. Read the full article on Seeking AlphaSeeking Alpha • Nov 28
Fortrea: Some Green Shoots After A Dismal Period
Summary Fortrea faces challenges with falling sales, lack of earnings, and high leverage, despite some positive signs in the third quarter. The company, spun off from Labcorp, operates in an interesting CRO sector, yet results are underwhelming. While leverage remains high, potential EBITDA improvements and reduced separation costs offer a roadmap for future growth, but risks like AI disruption remain. Read the full article on Seeking AlphaArticle d’analyse • Nov 21
There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding
Fortrea Holdings Inc.'s ( NASDAQ:FTRE ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...Rendement pour les actionnaires
| FTRE | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | -2.7% | 3.2% | 1.1% |
| 1Y | 225.6% | 8.3% | 28.7% |
Rendement vs Industrie: FTRE a dépassé le secteur US Life Sciences qui a rapporté 8.3 % au cours de l'année écoulée.
Rendement vs marché: FTRE a dépassé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 9.7% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: FTRE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de FTRE ( 10% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2023 | 14,000 | Anshul Thakral | www.fortrea.com |
Fortrea Holdings Inc. est un organisme de recherche sous contrat qui fournit des solutions de développement de produits biopharmaceutiques et d'appareils médicaux à des clients pharmaceutiques, biotechnologiques et d'appareils médicaux dans le monde entier. Elle propose des services de pharmacologie clinique, tels que des unités de recherche clinique, des partenariats externes, la gestion de projets, la conception et le suivi d'études, la bioanalyse et les biomarqueurs, la pharmacocinétique, la modélisation et la simulation, et la biométrie ; et des services de développement clinique, y compris des études cliniques de phase I à IV et des études de preuves en situation réelle, des affaires réglementaires, la conception de protocoles, la planification opérationnelle, le démarrage d'études et de sites, le recrutement de patients, la gestion de projets, le suivi complet de sites et la surveillance médicale, la gestion de données et la biostatistique, la pharmacovigilance, la rédaction médicale et les services cliniques mobiles. L'entreprise propose également des services de conseil en matière de développement de produits et de réglementation, d'accès au marché et d'économie de la santé, de recherche sur les résultats, ainsi que des services d'EEO.
Fortrea Holdings Inc. Résumé des fondamentaux
| FTRE statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.25b |
| Bénéfices(TTM) | -US$446.90m |
| Recettes(TTM) | US$2.71b |
0.5x
Ratio P/S-2.8x
Ratio P/ELe site FTRE est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| FTRE compte de résultat (TTM) | |
|---|---|
| Recettes | US$2.71b |
| Coût des recettes | US$2.20b |
| Marge brute | US$510.90m |
| Autres dépenses | US$957.80m |
| Les revenus | -US$446.90m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -4.72 |
| Marge brute | 18.86% |
| Marge bénéficiaire nette | -16.50% |
| Ratio dettes/capitaux propres | 200.4% |
Quelles ont été les performances à long terme de FTRE?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 16:08 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Fortrea Holdings Inc. est couverte par 13 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |